SLC16A1 and breast cancer: Johnson et al. [71] reported a higher risk of recurrence for MCT1-positive breast cancer patients independent of TNBC status when compared to MCT1-negative patients, in line with Sun et al. [73] and Li et al. [72] and findings, who reported a shorter DFS/recurrence-free survival (RFS) in different cohorts of breast cancer patients [71,72].